Anavex receives FDA clearance for Phase 2a Fragile X trial of blarcamesine
Anavex Life Sciences announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for blarcamesine in Fragile X syndrome. The company will launch a Phase 2a, randomized, double‑blind, placebo‑controlled study in approximately 60 adult male patients in the United States. The IND clearance adds Fragile X to the two other core indications—Alzheimer’s disease and Rett syndrome—where Anavex already holds open INDs. Blarcamesine also carries an FDA orphan‑drug designation for this indication.
Why it matters
The clearance permits Anavex to begin enrolling patients, moving the drug toward potential regulatory approval and future revenue streams. Investors will watch trial enrollment and safety data as early indicators of the program’s viability.
Key facts
- 1The FDA notified Anavex on Oct. 15, 2026 that it may proceed with the IND for blarcamesine in Fragile X syndrome. stocktitan.net
- 2The planned Phase 2a study will enroll approximately 60 adult male participants. stocktitan.net
- 3Anavex now has open INDs in three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome. stocktitan.net
- 4Blarcamesine has previously received FDA orphan‑drug designation for Fragile X syndrome. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.